| Management target | Revenue 11.0% FY27 |
|---|
| Revenue growth | 16% YoY growth driven by CDMO and new product launches. |
|---|---|
| Margins | EBITDA margin at 41.8% was boosted by one-time income. |
| Order book | Robust pipeline with 30 new high-potent API products. |
| Demand visibility | Strong demand in CDMO and specialized API segments across global markets. |
| Management confidence | High confidence in sustaining growth through pipeline execution and new facilities. |
Growth
Revenue grew 16% YoY; non-GPL business rose 20.8% and CDMO revenue jumped nearly 80% YoY.
Outlook
Management reaffirmed FY27 revenue growth guidance of 10-12% and EBITDA margins of 35-36%.
Risks
Normalization of high-margin new launch pricing and potential crude-led solvent cost escalation remain key risks.
Earnings Call Transcript filed with NSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,430.00
- Market cap
- ₹17,584 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 26.3×Sector 42.0×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Alivus Life Sciences Q2 FY27 Results: Net Profit ₹196.7 Cr, Up 51.3% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹682 Cr (+16.0% YoY) and net profit of ₹196.7 Cr (+51.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹196.7 Cr · +51.3% YoY
Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
Alivus Life Sciences Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.